Improving Enrollment for Challenging Protocol
A biopharma company developed an ingestible powder composed of nondigestible
oligosaccharides specifically for patients with ulcerative colitis (UC), with a goal of
positively affecting their gut microbiomes. The study needed to enroll 30 subjects
with mild to moderate UC symptoms both domestically and abroad. Elligo was
brought on to assist with enrolling 20 subjects in the U.S.
Download our case study to learn more.